Ask AI
ProCE Banner Activity

Towards Accessible and Equitable PrEP Implementation in Africa

Conference Coverage
Clinical Thought

The promise of long-acting antiretroviral drugs for HIV pre-exposure prophylaxis (PrEP) featured prominently at CROI 2026, while a study highlighted the very limited access to these transformative technologies in sub-Saharan Africa. Read on to learn what innovations in PrEP I found most exciting, and why PrEP is having a limited impact on HIV acquisition in Africa.

Released: March 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Andrew Mujugira, MBChB, MSc, MPH, PhD: consultant/advisor/speaker/researcher: Merck Sharpe & Dohme.